SCHEMBL6682928

SCHEMBL6682928

Cc1c2n(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)C=C(C(=O)OCc1ccc(F)cc1)NC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP12 P39900 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33
GAA P10253 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6682735 0.86 KDM4E (0.38) NPC1RAB9AALDH1A1KDM4EMAPT
SCHEMBL6680959 0.85 ALDH1A1 (0.38) RAB9AALDH1A1KDM4ETSHRPTGDR2
SCHEMBL6679307 0.84 TRPA1 (0.43) TP53ALDH1A1MAPTTSHRGAA
SCHEMBL6681574 0.82 ALDH1A1 (0.36) TP53NPC1RAB9AALDH1A1KDM4E
SCHEMBL6679240 0.82 TP53 (0.36) TP53NPC1RAB9AALDH1A1KDM4E
SCHEMBL6683316 0.71 TRPA1 (0.44) RAB9AALDH1A1KDM4EMAPTCNR1
SCHEMBL6684992 0.71 TRPA1 (0.39) RAB9AKDM4EPKMTSHRLMNA
SCHEMBL6683536 0.70 TRPA1 (0.45) TP53ALDH1A1MAPTGAA
SCHEMBL6685075 0.70 TRPA1 (0.43) TP53ALDH1A1MAPTTSHRGAA
SCHEMBL6679418 0.70 PTGDR2 (0.36) RAB9AALDH1A1KDM4ETSHRPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP11 TP53 2960/4885NPC1 1882/4885RAB9A 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.